Large Language Models for Gastrointestinal Clinical Reasoning

Abstract

Large language models (LLMs) have rapidly emerged as transformative tools in medicine, offering the potential to augment clinical reasoning, diagnostic decision-making, and management pathways in gastrointestinal (GI) diseases. This review critically examines the integration of LLMs within GI clinical workflows, focusing on epidemiology, pathophysiology, risk stratification, diagnostic accuracy, therapeutic guidance, recent advances, and evolving guideline recommendations. Emphasis is placed on the scientific underpinnings, practical implications, and real-world challenges of deploying LLMs to support gastroenterologists and multidisciplinary teams. Clinical relevance is highlighted by the potential for improved diagnostic precision, tailored management, and streamlined care pathways, balanced against concerns regarding bias, interpretability, and implementation barriers.

Introduction

Gastrointestinal disorders, ranging from functional bowel syndromes to complex malignancies, pose significant diagnostic and therapeutic challenges in clinical practice. The increasing volume and complexity of medical data have outpaced the cognitive capacity of individual clinicians, necessitating innovative decision support tools. Large language models, trained on vast corpora of biomedical literature and clinical data, are poised to bridge this gap by synthesizing evidence, generating differential diagnoses, and recommending personalized management strategies. This article provides an evidence-based, guideline-oriented review of LLMs for gastrointestinal clinical reasoning, tailored for healthcare professionals seeking to understand and harness these technologies in daily practice.

Epidemiology / Disease Burden

Gastrointestinal diseases account for a substantial proportion of global morbidity and healthcare utilization. Chronic liver diseases, inflammatory bowel disease (IBD), colorectal cancer, and functional gastrointestinal disorders such as irritable bowel syndrome (IBS) collectively affect hundreds of millions worldwide. Diagnostic delays, misclassifications, and variations in care contribute to adverse outcomes and escalating costs. The burden is further compounded by aging populations and rising prevalence of lifestyle-related risk factors. LLMs offer scalable solutions to address these epidemiologic challenges by facilitating timely and accurate clinical reasoning, thus potentially reducing diagnostic errors and care disparities.

Pathophysiology

LLMs contribute to the understanding and application of GI pathophysiology by integrating multilevel biomedical knowledge ranging from molecular mechanisms to organ-level dysfunction. For instance, in IBD, LLMs can synthesize literature on immune dysregulation, genetic susceptibility, and gut microbiome alterations to provide nuanced explanations and support complex diagnostic distinctions. Similarly, in hepatology, LLMs can contextualize biochemical pathways, fibrosis progression, and oncogenic mechanisms, informing both clinical and research decisions. Their ability to parse and relate diverse mechanistic data enhances the clinician’s capacity for mechanism-based reasoning in GI disease states.

Risk Factors

Accurate risk stratification is fundamental to GI clinical care. LLMs can dynamically assess patient-specific and population-level risk factors by integrating demographic, genetic, lifestyle, and comorbid data. For example, in colorectal cancer screening, LLMs can personalize risk assessment by combining family history, polygenic risk scores, and environmental exposures. In chronic liver disease, LLMs can synthesize alcohol use, metabolic syndrome parameters, and viral hepatitis status to predict progression and inform surveillance intervals. This approach supports precision medicine, enabling stratified prevention and early intervention strategies in GI disorders.

Clinical Features

LLMs excel at mapping and correlating the wide spectrum of clinical features seen in GI diseases. By analyzing structured and unstructured clinical data, including symptom descriptions, laboratory findings, and imaging reports, LLMs can generate prioritized differential diagnoses. For instance, distinguishing between Crohn’s disease and ulcerative colitis, or between functional and organic GI disorders, relies on subtle pattern recognition across diverse data sets a task well suited to advanced LLM architectures. Clinicians benefit from rapid synthesis of relevant features, minimizing cognitive overload and improving diagnostic accuracy.

Diagnosis

Diagnostic decision-making in gastroenterology is inherently complex, often requiring integration of multiple data modalities. LLMs can augment this process by synthesizing guidelines, recent studies, and patient-specific data to recommend evidence-based diagnostic pathways. For example, LLMs can suggest appropriate serologic, endoscopic, and histopathologic investigations for suspected celiac disease or chronic diarrhea, ensuring adherence to best practices. Moreover, LLMs can flag atypical presentations or diagnostic pitfalls, prompting clinicians to consider rare entities or pursue further evaluation, thereby reducing missed or delayed diagnoses.

Treatment & Management

LLMs are increasingly capable of supporting therapeutic decision-making by contextualizing pharmacologic, endoscopic, and surgical options within the framework of current guidelines and the individual patient profile. In IBD, LLMs can recommend biologic therapies based on disease phenotype, prior response, and comorbidities. In hepatology, they can assist in antiviral regimen selection or cirrhosis management. Importantly, LLMs can also facilitate shared decision-making by generating patient-friendly explanations and highlighting treatment trade-offs, thereby enhancing patient engagement and adherence.

Recent Advances / Emerging Therapies

The integration of LLMs into electronic health records (EHRs), clinical decision support systems, and virtual care platforms represents a recent and rapidly evolving advance. Emerging research demonstrates that LLM-augmented systems can improve diagnostic accuracy, reduce time to diagnosis, and optimize resource utilization in GI care. Innovative applications include automated endoscopic report generation, natural language triage of referrals, and real-time synthesis of guideline updates. Further, LLMs are facilitating clinical trial matching and pharmacovigilance by continuously scanning the literature and patient data for relevant associations and safety signals.

Guideline Recommendations

Major gastroenterology societies are increasingly acknowledging the potential and challenges of AI and LLMs in clinical practice. Consensus statements emphasize the importance of transparency, validation, and clinician oversight in LLM deployment. Guidelines recommend integrating LLM-based tools as adjuncts not replacements for clinician judgment, with robust governance to ensure patient safety and data security. Ongoing guideline updates are expected as the evidence base matures, with calls for multidisciplinary collaboration in the safe, ethical, and effective implementation of LLMs in GI medicine.

Conclusion

Large language models are poised to reshape gastrointestinal clinical reasoning by enhancing diagnostic precision, risk stratification, and personalized management. While early evidence supports their utility across multiple facets of GI care, challenges remain regarding model interpretability, bias mitigation, and integration into existing clinical workflows. Continued research, rigorous validation, and adherence to evolving guidelines will be essential for realizing the full potential of LLMs in gastroenterology and delivering improved patient outcomes.